Uric acid
|
Basic information |
| Metabolite name | Uric acid |
 | HMDB0000289 |
 |
C00366 |
 |
1175 |
| Synonyms | Urate |
| No. of studies | 25 |
|
Basic information |
| Metabolite name | Uric acid |
| HMDB0000289 |
|
C00366 |
|
1175 |
| Synonyms | Urate |
| No. of studies | 25 |
|
Relationship between Uric acid and depression (count: 25) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Down |
| Study M037 | Type2 | sertraline treatment group one-week vs. baseline | Serum | Human | Down |
| Study M095 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M480 | Type2 | CGA-treated group vs. sleep deprivation group | Urine | Wistar rat | Up |
| Study M532 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M556 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Nucleus accumbens | C57BL/6 J mouse | Up |
| Study M617 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Up |
| Study M617 | Type2 | CUMS + ellagic acid group vs. CUMS group | Serum | C57BL/6 mouse | Down |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M651 | Type1 | LPS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M651 | Type2 | LPS + fish oil group vs. LPS group | Brain | C57BL/6 mouse | Down |
| Study M668 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
| Study M898 | Type1 | end-stage renal disease with depression group vs. end-stage renal disease without depression group | Serum | Human | Up |
| Study M953 | Type2 | CRS + Shugan Granule group vs. CRS group | Faece | Sprague-Dawley rat | Up |
| Study M957 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 J mouse | Down |
| Study M957 | Type1 | CSDS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M980 | Type1 | CMS group vs. control group | Olfactory bulb | C57BL/6J mouse | Up |